Vera Therapeutics (Vera Therapeutics) Float Percentage Of Total Shares Outstanding : 67.73% (As of May. 28, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Vera Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Vera Therapeutics's float shares is 37.05 Mil. Vera Therapeutics's total shares outstanding is 54.70 Mil. Vera Therapeutics's float percentage of total shares outstanding is 67.73%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Vera Therapeutics's Insider Ownership is 0.94%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Vera Therapeutics's Institutional Ownership is 34.94%.

Vera Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Vera Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	37.05	/	54.70
	=	67.73%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vera Therapeutics (Vera Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vera Therapeutics Inc (NAS:VERA) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

8000 Marina Boulevard, Suite 120, Brisbane, CA, USA, 94005

Website

https://www.veratx.com

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Executives

Commodore Capital Lp	10 percent owner	444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Marshall Fordyce	director, officer: President and CEO	C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Celia Lin	officer: Chief Medical Officer	C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Joanne Curley	officer: Chief Development Officer	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Sean Grant	officer: Chief Financial Officer	C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Beth C Seidenberg	director
Sofinnova Management X-a, L.l.c.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Longitude Capital Partners Iv, Llc	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Partners, Llc	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Fund, L.p.	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Patrick G Enright	director, 10 percent owner	CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Llp Abingworth	10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN
Abingworth Bioventures 8 Lp	10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN
Carlyle Group Inc.	10 percent owner	C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004